ALNYLAM PHARMACEUTICALS, INC. (ALNY) Operating income 2016–2025
ALNYLAM PHARMACEUTICALS, INC. (ALNY) annual operating income history from SEC filings — each fiscal year as reported.
$501.6MFY2025 · since FY2016: -$424.6M → $501.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $501.6M | +383.6% |
| FY2024 | -$176.9M | +37.3% |
| FY2023 | -$282.2M | +64.1% |
| FY2022 | -$785.1M | -10.8% |
| FY2021 | -$708.7M | +14.5% |
| FY2020 | -$828.4M | +11.8% |
| FY2019 | -$939.4M | -15.3% |
| FY2018 | -$814.7M | -62.9% |
| FY2017 | -$500.1M | -17.8% |
| FY2016 | -$424.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ALNY financial trends
ALNY RevenueALNY Net incomeALNY Net marginALNY Gross profitALNY Gross marginALNY Operating marginALNY Operating cash flowALNY Free cash flowALNY Capital expendituresALNY Return on equityALNY Stock buybacksALNY Dividends paidALNY Total assetsALNY Total liabilitiesALNY Shareholders’ equityALNY overview →